Consun Pharma
Consun Pharma, officially known as China Consun Pharmaceutical Group, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions. With a strong operational presence across Asia and expanding into international markets, Consun Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic drugs, particularly in the fields of cardiovascular health and anti-infectives, distinguished by their efficacy and safety profiles. Notably, Consun Pharma has achieved several milestones, including certifications from international regulatory bodies, which solidify its market position as a trusted provider in the global pharmaceutical landscape.
DitchCarbon Score
How does Consun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consun Pharma's score of 25 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Consun Pharma's reported carbon emissions
In 2023, Consun Pharma, headquartered in China (CN), reported total carbon emissions of approximately 79,125,220 kg CO2e. This figure includes about 54,210,460 kg CO2e from Scope 1 emissions and about 24,914,760 kg CO2e from Scope 2 emissions. Compared to 2022, when total emissions were about 72,057,200 kg CO2e, this represents an increase in emissions. Consun Pharma has set ambitious climate commitments, aiming to reduce its combined Scope 1 and 2 greenhouse gas emissions by 54.6% from a 2023 baseline by the year 2033. This long-term target reflects the company's commitment to sustainability and aligns with industry standards for climate action. The company does not currently disclose Scope 3 emissions data, which often includes indirect emissions from the supply chain and product use. However, the focus on reducing Scope 1 and 2 emissions indicates a proactive approach to managing its direct and energy-related emissions. Overall, Consun Pharma's emissions data and reduction targets highlight its ongoing efforts to address climate change and improve its environmental impact within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000.0 | 00,000,000 |
| Scope 2 | 7,978,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Consun Pharma is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
